584 related articles for article (PubMed ID: 33948121)
1. Cost-effectiveness of ribociclib plus letrozole
Buehler AM; Castilho G; Dionne PA; Stefani S
Ther Adv Med Oncol; 2021; 13():17588359211000593. PubMed ID: 33948121
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom.
Suri G; Chandiwana D; Lee A; Mistry R
J Health Econ Outcomes Res; 2019; 6(2):20-31. PubMed ID: 32685577
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.
Galve-Calvo E; González-Haba E; Gostkorzewicz J; Martínez I; Pérez-Mitru A
Clinicoecon Outcomes Res; 2018; 10():773-790. PubMed ID: 30532569
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model.
Darvishi A; Daroudi R; Fazaeli AA
Health Econ Rev; 2023 Nov; 13(1):53. PubMed ID: 37943359
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
[No Abstract] [Full Text] [Related]
9. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
[TBL] [Abstract][Full Text] [Related]
10. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole
Jhaveri K; O'Shaughnessy J; Fasching PA; Tolaney SM; Yardley DA; Sharma VK; Biswas C; Thuerigen A; Pathak P; Rugo HS
Ther Adv Med Oncol; 2023; 15():17588359231216095. PubMed ID: 38107828
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.
Rosa DD; Magliano CADS; Simon SD; Amorim G; Reinert T; Landeiro L; Gagliato DM; Exman P; Argolo D; Guilgen G; Mano M; Testa L; Liedke P; Barroso R; Sasse M; Buehler AM
Ther Adv Med Oncol; 2022; 14():17588359221100865. PubMed ID: 36339925
[TBL] [Abstract][Full Text] [Related]
13. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Zhang B; Long EF
Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
[TBL] [Abstract][Full Text] [Related]
15. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico.
Molina-Jaimes M; Galindo-González A; Verduzco-Aguirre HC; Bautista-Arredondo S; Reyes-Terán G; Soto-Perez-de-Celis E
Clin Transl Oncol; 2024 Jan; 26(1):239-244. PubMed ID: 37329428
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis.
Zeng N; Han J; Liu Z; He J; Tian K; Chen N
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444496
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
20. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
